FDA under Makary will accelerate rare disease drug approvals by Q1 2026

Makary's tenure has prioritized speeding up drug approvals and clinical trials, particularly for rare diseases. His continued leadership would ensure these initiatives remain a priority, with measurable outcomes visible in public FDA approvals and policy updates by early 2026.

Implied probability (Yes)

75%